Key result
Leadless pacemaker revision and removal rates drop ~81% from 2016 to 2021 alongside stable readmissions.
Why the study?
Leadless pacemaker utilization has grown significantly, but data on removal and/or revision remains limited.
What are the trends in 30-day readmission, mortality, and resource utilization following leadless pacemaker revision and removal?
Observational
Yes
What are the trends in 30-day readmission, mortality, and resource utilization following leadless pacemaker revision and removal?
Despite rapid growth in leadless pacemaker implantations, the rates of revision and removal have significantly declined, with stable 30-day readmission and mortality outcomes.
Answers are grounded in this paper and cite their sources.
Declining revision rates with stable readmissions suggest maturing leadless pacemaker use; leaves open whether outcomes improve with wider adoption.
Background: Leadless pacemakers (LPM) utilization has grown significantly, yet data on LPM removal and/or revision (LPM-RR) remains limited. This study aims to evaluate trends in 30-day readmission rate (30-dRr), mortality, and resource utilization associated with LPM-RR Method: We analyzed data from the Nationwide Readmission Database from 2016 to 2021. Patients ≥ 18 years who underwent LPM-RR were identified using ICD-10 codes. The primary outcome was the trend on 30-dRr following LPM-RR. Secondary outcomes included mortality, resource utilization (Length of stay {LOS}&inflation-adjusted mean hospital cost),&most common readmission diagnosis. Predictive marginal effects over the years®ression analyses were conducted. Results: LPMs placement increased from 350 in 2016 to 16,225 in 2021 (p-trend < 0.001), while the rate of revisions and removals declined from 6.2% to 1.2% (p-trend < 0.001). The mean age at index admission was 70.9 years with 51.6% females, compared to 71.6 years and 60.8% males among readmitted patients. The 30-dRr increased slightly from 13.8% in 2016 to 16% in 2021 (p trend = 0.1). Index admission mortality trends were non-significant, decreasing from 7.4% in 2017 to 4.2% in 2021 (p-trend = 0.4). Readmission mortality trends also remained non-significant, from 8.3% in 2016 to 8.4% in 2021 (p-trend = 0.3). The index admission mean LOS was 12.1 days in 2016 to 10.2 days in 2021 (p trend = 0.09), while readmission mean LOS was 4.1 days to 3.8 days (p trend = 0.9). The inflation-adjusted mean hospital cost for index admissions decreased from $76,432.5 in 2016 to $61,501 in 2021 (p trend = 0.08), whereas readmission costs increased from $6,773 to $9,358 (p-trend = 0.7). The most common reason for readmission was hypertensive heart disease with heart failure. Conclusion: From 2016 to 2021, LPM implantation grew rapidly with a significant decline in revision and removal rates. During this period, 30-dRr&resource utilization have remained relatively stable, with a trend toward decreasing mortality within 30 days after LPM implantation, likely owing to technology/technique advancements, increased experience, as well as patient selection. Further research is needed to assess outcomes for the rapidly evolving use of LPM in an increasingly broader range of patient populations.
No takes yet. Share an insight, caveat, or question.
Fatuyi et al. (2024) conducted an observational in Leadless pacemaker revision and removal. Leadless pacemaker revision and removal (LPM-RR) was evaluated on Trend in 30-day readmission rate following LPM-RR (p=0.1). Leadless pacemaker revision and removal rates declined from 6.2% to 1.2% between 2016 and 2021, with 30-day readmission rates remaining stable from 13.8% to 16.0%.
Synapse has enriched 10 related papers. Consider them for comparative context: